What's Happening?
In the Union Budget 2026, Finance Minister Nirmala Sitharaman announced a significant allocation of ₹10,000 crore to enhance India's biopharma manufacturing capabilities. The initiative, named 'Biopharma
SHAKTI', aims to position India as a global hub for biopharma production. It includes establishing new National Institutes of Pharmaceutical Education and Research and upgrading existing ones, as well as creating a network of clinical trial sites. The budget also proposes strengthening the Central Drugs Standard Control Organisation to align with global standards. These measures are part of a broader strategy to reduce dependency on imports and enhance domestic production of biologics and biosimilars.
Why It's Important?
This initiative is a strategic move to bolster India's healthcare infrastructure and reduce reliance on imported pharmaceuticals. By investing in biopharma manufacturing, India aims to address the growing burden of non-communicable diseases and enhance its status as the 'Pharmacy of the World'. The focus on domestic production of biologics and biosimilars is expected to lower costs for critical therapies and improve access to essential medicines. This aligns with India's broader goal of achieving self-reliance in healthcare and becoming a developed nation by 2047. The initiative is also likely to drive innovation, job creation, and attract global investments.
What's Next?
The implementation of the 'Biopharma SHAKTI' initiative will involve setting up new educational and research institutions, as well as expanding clinical trial capabilities. The government will work on strengthening regulatory frameworks to ensure timely approvals and global alignment. Industry stakeholders, including pharmaceutical companies and research organizations, are expected to collaborate with the government to achieve these objectives. The success of this initiative will depend on effective execution and continued investment in research and development. As the initiative progresses, it could significantly enhance India's role in the global biopharma landscape.
